Comprehensive Market Update – CRO Industry 2023

Nephron Life Sciences and Tools analyst Jack Meehan published a comprehensive market update last week on the CRO industry entering 2023. Jack and team think the overall industry outlook continues to look mixed, with sluggish capital markets activity and hiring data. The large CROs appear to be increasingly leaning on pharma relationships as biotech spending patterns have slowed. On a positive note, Thermo Fisher’s PPD is turning heads given the company’s growth and bullish commentary. Jack thinks there may be a few factors driving Thermo Fisher’s outsized growth.  For additional information on this report and Nephron Research, please email: